Erratum: Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: Results of a randomised double-blind placebo-controlled study (SPINE) (Annals of the Rheumatic Diseases (2011) 70, (799-804) DOI:10.1136/ard.2010.139261);Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: Results of a randomised double-blind placebo-controlled study (SPINE)

Annals of the Rheumatic Diseases

Volumn 70, Issue 5, 2011, Pages 799-804

  Dougados, Maxime ^a,b   Braun, J ^c   Szanto, S ^d   Combe, B ^e   Elbaz, M ^f   Geher, P ^g   Thabut, G ^a   Leblanc, V ^h   Logeart, I ^h  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Cochin Hospital ^*  (France)

^c RHEUMAZENTRUM RUHRGEBIET   (Germany)

^d UNIVERSITY OF DEBRECEN   (Hungary)

^e LAPEYRONIE HOSPITAL   (France)

^f Medical Center   (France)

^g Polyclinic of the Hospitaller Brothers of St John of God ^*  (Hungary)

^h PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; ETANERCEPT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; BACKACHE; BATH AS DISEASE ACTIVITY INDEX; BATH AS METROLOGY INDEX; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FORCED VITAL CAPACITY; HUMAN; INJECTION SITE REACTION; LUNG FUNCTION TEST; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATIC DISEASE; SPINE MOBILITY; TREATMENT RESPONSE;

EID: 79953321992     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.139261corr1     Document Type: Erratum

References (35)

1. Dougados M, LandewéR. Spondyloarthritides: pathogenesis, clinical aspect and diagnosis. In:Bijlsma J, ed. EULAR Compendium on Rheumatic Diseases. London: BMJ Publishing Group 2009:92-116.
2. Boonen A, van der Linden SM. The burden of ankylosing spondylitis. J Rheumatol Suppl 2006;78:4-11. (Pubitemid 44360187)
3. Feltelius N, Hedenström H, Hillerdal G, et al. Pulmonary involvement in ankylosing spondylitis. Ann Rheum Dis 1986;45:736-40. (Pubitemid 16016854)
4. Sampaio-Barros PD, Cerqueira EM, Rezende SM, et al. Pulmonary involvement in ankylosing spondylitis. Clin Rheumatol 2007;26:225-30. (Pubitemid 46020249)
5. Fisher LR, Cawley MI, Holgate ST. Relation between chest expansion, pulmonary function, and exercise tolerance in patients with ankylosing spondylitis. Ann Rheum Dis 1990;49:921-5. (Pubitemid 20360758)
6. Davis JC Jr, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6. (Pubitemid 37409337)
7. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis:results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91. (Pubitemid 40216323)
8. van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis:results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:2136-46. (Pubitemid 44051069)
9. Heiberg MS, Nordvåg BY, Mikkelsen K, et al. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis:a six-month, longitudinal, observational, multicenter study. Arthritis Rheum 2005;52:2506-12. (Pubitemid 41117438)
10. Cheung PP, Tymms KE, Wilson BJ, et al. Infliximab in severe active ankylosing spondylitis with spinal ankylosis. Intern Med J 2008;38:396-401. (Pubitemid 351871972)
11. Rudwaleit M, Olivieri I, Boki KA, et al. Adalimumab is effective and well tolerated in treating patients with ankylosing spondylitis who have advanced spinal fusion. Rheumatology (Oxford) 2009;48:551-7.
12. van der Heijde D, Pangan AL, Schiff MH, et al.;ATLAS Study Group. Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. Ann Rheum Dis 2008;67:1218-21.
13. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
14. van der Heijde D, LandewéR. Selection of a method for scoring radiographs for ankylosing spondylitis clinical trials, by the Assessment in Ankylosing Spondylitis Working Group and OMERACT. J Rheumatol 2005;32:2048-9.
15. Braun J, van der Heijde, Dougados M, et al. Staging of patients with ankylosing spondylitis. Ann Rheum Dis 2002;61 (Suppl III):iii19-23.
16. MacKay K, Brophy S, Mack C, et al. The development and validation of a radiographic grading system for the hip in ankylosing spondylitis: the Bath Ankylosing Spondylitis Radiology Hip Index. J Rheumatol 2000;27:2866-72.
17. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis:the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
18. Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis:the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
19. Jenkinson TR, Mallorie PA, Whitelock HC, et al. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994;21:1694-8. (Pubitemid 24285485)
20. van der Heijde D, LandewéR, Feldtkeller E. Proposal of a linear definition of the Bath Ankylosing Spondylitis Metrology Index (BASMI) and comparison with the 2-step and 10-step definitions. Ann Rheum Dis 2008;67:489-93.
21. Tubach F, Ravaud P, Baron G, et al. Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis:the minimal clinically important improvement. Ann Rheum Dis 2005;64:29-33. (Pubitemid 40075270)
22. Tubach F, Ravaud P, Baron G, et al. Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis:the patient acceptable symptom state. Ann Rheum Dis 2005;64:34-7. (Pubitemid 40075271)
23. Anon. Seconde édition française des recommandations européennes pour les explorations fonctionnelles respiratiores. Rev Mal Respir 2001;18:6S7-6S119.
24. Lukas C, LandewéR, Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:18-24.
25. Anderson JJ, Baron G, van der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86. (Pubitemid 32758236)
26. Machado P, LandewéR, Lie E, et al. Ankylosing spondylitis disease activity score (ASDAS):defining criteria for disease activity states and improvement scores. Ann Rheum Dis 2010;69 (Suppl 3):OP0131.
27. Brandt J, Listing J, Sieper J, et al. Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis 2004;63:1438-44. (Pubitemid 39433948)
28. van der Heijde D, LandewéR, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008;58:1324-31.
29. van der Heijde D, LandewéR, Baraliakos X, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008;58:3063-70.
30. van der Heijde D, Salonen D, Weissman BN, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009;11:R127.
31. Braun J, Huang F, Burgos-Vargas R, et al. Assessment of clinical efficacy in a randomized, double-blind study of etanercept and sulphasalazine in patients with ankylosing spondylitis. Arthritis Rheum 2008;58 (Suppl 9):S415 (673).
32. van der Heijde D, Lie E, Kvien TK, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:1811-8.
33. van der Heijde D, Da Silva JC, Dougados M, et al. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:1572-7. (Pubitemid 44799667)
34. Sieper J, Rudwaleit M. How early should ankylosing spondylitis be treated with tumour necrosis factor blockers? Ann Rheum Dis 2005;64 (Suppl 4):iv61-4.
35. Quismorio FP Jr. Pulmonary involvement in ankylosing spondylitis. Curr Opin Pulm Med 2006;12:342-5.